SRR815232
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- DNA_REPAIR+0.231
- MYOGENESIS+0.230
- UNFOLDED_PROTEIN_RESPONSE+0.181
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.160
- UV_RESPONSE_UP+0.145
- PI3K_AKT_MTOR_SIGNALING+0.130
- WNT_BETA_CATENIN_SIGNALING+0.121
- KRAS_SIGNALING_DN+0.088
- MYC_TARGETS_V1+0.083
- P53_PATHWAY+0.071
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.469
- INTERFERON_GAMMA_RESPONSE-0.429
- ALLOGRAFT_REJECTION-0.338
- INFLAMMATORY_RESPONSE-0.332
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.327
- KRAS_SIGNALING_UP-0.324
- PANCREAS_BETA_CELLS-0.308
- IL6_JAK_STAT3_SIGNALING-0.301
- TNFA_SIGNALING_VIA_NFKB-0.286
- COMPLEMENT-0.228
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR814563 | GTEX | — | 0.883 |
| 2 | SRR1401062 | GTEX | — | 0.855 |
| 3 | SRR1417981 | GTEX | — | 0.854 |
| 4 | SRR1307770 | GTEX | — | 0.854 |
| 5 | SRR1335377 | GTEX | — | 0.849 |
| 6 | SRR663681 | GTEX | — | 0.849 |
| 7 | SRR1398839 | GTEX | — | 0.846 |
| 8 | SRR1331944 | GTEX | — | 0.844 |
| 9 | SRR1097752 | GTEX | — | 0.843 |
| 10 | SRR1394799 | GTEX | — | 0.842 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| DNA_REPAIR | 0.231 | Idelalisib | — uncovered |
| MYOGENESIS | 0.230 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.181 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.160 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.145 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.130 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.121 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.088 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.083 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.071 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.057 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.052 | Temsirolimus | — uncovered |
| HEME_METABOLISM | 0.049 | Temsirolimus | — uncovered |
| PEROXISOME | 0.043 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.009 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.009 | Inavolisib | — uncovered |